Q1 beat; full-year guidance re-affirmed
26/04/24 -"The Q1 profits surpassed the street’s expectations, as all the three key molecules witnessed decent growth. Segment-wise, Spain and International were the main drivers behind the Q1 performance. ..."
Pages
45
Language
English
Published on
26/04/24
You may also be interested by these reports :
07/05/24
Q1 sales missed the consensus estimates, although the CER growth was largely in line with the firm’s full-year outlook. Biosimilars were the main ...
03/05/24
Genmab’s Q1 sales exceeded expectations, although profitability fell somewhat short. This robust performance was led by strong growth across all the ...
03/05/24
We have rolled forward our model to include a new forecast year (2026) which will also see continued healthy top-line growth and profitability ...
02/05/24
CureVac did not really tidy things up. The cost-cutting measures, as presented, are insufficient and do not meet our ideal scenario of a focused and ...